Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research (Q34401653)

1 August 2017

Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research (English)

1 reference

amyotrophic lateral sclerosis

1 August 2017

0 references

1 reference

Xiaowei W Su

1

0 references

James Broach

object named as

James R Broach

2

0 references

author name string

James R Connor

3

1 reference

PubMed ID

24488689

1 August 2017

Glenn S Gerhard

4

1 reference

PubMed ID

24488689

1 August 2017

Zachary Simmons

5

1 reference

1 August 2017

8 April 2014

1 reference

1 August 2017

1 reference

1 August 2017

49

1 reference

1 August 2017

6

1 reference

1 August 2017

786-803

1 reference

The epidemiology of ALS and the role of population-based registries

1 August 2017

1 reference

Genetic epidemiology of amyotrophic lateral sclerosis

21 January 2018

1 reference

Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature

21 January 2018

1 reference

Prognostic categories for amyotrophic lateral sclerosis

21 January 2018

1 reference

Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study

21 January 2018

1 reference

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

21 January 2018

1 reference

Survival in frontotemporal dementia

21 January 2018

1 reference

Motor neuron dysfunction in frontotemporal dementia.

21 January 2018

1 reference

Prevalence and patterns of cognitive impairment in sporadic ALS.

21 January 2018

1 reference

The cognitive profile of amyotrophic lateral sclerosis: A meta-analysis

21 January 2018

1 reference

Neuroprotective agents for clinical trials in ALS: a systematic assessment

21 January 2018

1 reference

The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials

21 January 2018

1 reference

How can we improve clinical trials in amyotrophic lateral sclerosis?

21 January 2018

1 reference

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

21 January 2018

1 reference

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

21 January 2018

1 reference

Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase

21 January 2018

1 reference

TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6

21 January 2018

1 reference

Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia

21 January 2018

1 reference

A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis

21 January 2018

1 reference

Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis

21 January 2018

1 reference

Strategies for multilocus linkage analysis in humans

21 January 2018

1 reference

Genetic diagnosis by whole exome capture and massively parallel DNA sequencing

21 January 2018

1 reference

Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis

21 January 2018

1 reference

Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease

21 January 2018

1 reference

Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study

21 January 2018

1 reference

Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis

21 January 2018

1 reference

Clinical genetics of amyotrophic lateral sclerosis: what do we really know?

21 January 2018

1 reference

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS

21 January 2018

1 reference

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD

21 January 2018

1 reference

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

21 January 2018

1 reference

Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS.

21 January 2018

1 reference

ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics

21 January 2018

1 reference

The changing scene of amyotrophic lateral sclerosis

21 January 2018

1 reference

Age and founder effect of SOD1 A4V mutation causing ALS

21 January 2018

1 reference

Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease.

21 January 2018

1 reference

The complex molecular biology of amyotrophic lateral sclerosis (ALS)

21 January 2018

1 reference

Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response.

21 January 2018

1 reference

Autophagy dysregulation in amyotrophic lateral sclerosis.

21 January 2018

1 reference

Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis

21 January 2018

1 reference

Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice

21 January 2018

1 reference

Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons

21 January 2018

1 reference

Astrocytes from familial and sporadic ALS patients are toxic to motor neurons

21 January 2018

1 reference

Pathophysiological insights into ALS with C9ORF72 expansions.

21 January 2018

1 reference

Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72.

21 January 2018

1 reference

Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study

21 January 2018

1 reference

Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis

21 January 2018

1 reference

Frontotemporal dementia with amyotrophic lateral sclerosis: a clinical comparison of patients with and without repeat expansions in C9orf72.

21 January 2018

1 reference

Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis

21 January 2018

1 reference

Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia.

21 January 2018

1 reference

Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration

21 January 2018

1 reference

RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention

21 January 2018

1 reference

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

21 January 2018

1 reference

Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS

21 January 2018

1 reference

The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS.

21 January 2018

1 reference

Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion

21 January 2018

1 reference

TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis

21 January 2018

1 reference

Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease.

21 January 2018

1 reference

Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43.

21 January 2018

1 reference

TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor

21 January 2018

1 reference

TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1.

21 January 2018

1 reference

FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis.

21 January 2018

1 reference

Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations

21 January 2018

1 reference

21 January 2018

1 reference

Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs

21 January 2018

1 reference

Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS

21 January 2018

1 reference

Reactive astrocytes secrete lcn2 to promote neuron death

21 January 2018

1 reference

Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats

21 January 2018

1 reference

Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons.

21 January 2018

1 reference

New VAPB deletion variant and exclusion of VAPB mutations in familial ALS.

21 January 2018

1 reference

Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis

21 January 2018

1 reference

ALS-linked P56S-VAPB, an aggregated loss-of-function mutant of VAPB, predisposes motor neurons to ER stress-related death by inducing aggregation of co-expressed wild-type VAPB.

21 January 2018

1 reference

The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors

21 January 2018

1 reference

Amyotrophic lateral sclerosis-linked mutant VAPB enhances TDP-43-induced motor neuronal toxicity

21 January 2018

1 reference

Exome sequencing reveals VCP mutations as a cause of familial ALS

21 January 2018

1 reference

Novel mutation in VCP gene causes atypical amyotrophic lateral sclerosis

21 January 2018

1 reference

Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

Neuronal-specific overexpression of a mutant valosin-containing protein associated with IBMPFD promotes aberrant ubiquitin and TDP-43 accumulation and cognitive dysfunction in transgenic mice.

21 January 2018

1 reference

Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels

21 January 2018

1 reference

Ubiquilin 2 mutations in Italian patients with amyotrophic lateral sclerosis and frontotemporal dementia

21 January 2018

1 reference

Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype.

21 January 2018

1 reference

Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion

21 January 2018

1 reference

The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis

21 January 2018

1 reference

Alsin and the molecular pathways of amyotrophic lateral sclerosis

21 January 2018

1 reference

The first ALS2 missense mutation associated with JPLS reveals new aspects of alsin biological function

21 January 2018

1 reference

Alsin, the product of ALS2 gene, suppresses SOD1 mutant neurotoxicity through RhoGEF domain by interacting with SOD1 mutants

21 January 2018

1 reference

Alsin and SOD1(G93A) proteins regulate endosomal reactive oxygen species production by glial cells and proinflammatory pathways responsible for neurotoxicity

21 January 2018

1 reference

Amyotrophic lateral sclerosis 2-deficiency leads to neuronal degeneration in amyotrophic lateral sclerosis through altered AMPA receptor trafficking

21 January 2018

1 reference

Regulation of endosomal motility and degradation by amyotrophic lateral sclerosis 2/alsin

21 January 2018

1 reference

Alsin/Rac1 signaling controls survival and growth of spinal motoneurons

21 January 2018

1 reference

Astrocytic protection of spinal motor neurons but not cortical neurons against loss of Als2/alsin function.

21 January 2018

1 reference

DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4)

21 January 2018

1 reference

Senataxin mutations and amyotrophic lateral sclerosis

21 January 2018

1 reference

Senataxin associates with replication forks to protect fork integrity across RNA-polymerase-II-transcribed genes

21 January 2018

1 reference

Senataxin modulates neurite growth through fibroblast growth factor 8 signalling

21 January 2018

1 reference

Mutations of optineurin in amyotrophic lateral sclerosis

21 January 2018

1 reference

Differential involvement of optineurin in amyotrophic lateral sclerosis with or without SOD1 mutations

21 January 2018

1 reference

Toward an integrative view of Optineurin functions

21 January 2018

1 reference

Optineurin suppression causes neuronal cell death via NF-κB pathway.

21 January 2018

1 reference

Ubiquitin-independent function of optineurin in autophagic clearance of protein aggregates

21 January 2018

1 reference

ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis.

21 January 2018

1 reference

Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis

21 January 2018

1 reference

Lack of unique neuropathology in amyotrophic lateral sclerosis associated with p.K54E angiogenin (ANG) mutation

21 January 2018

1 reference

Control of motoneuron survival by angiogenin.

21 January 2018

1 reference

Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor neurons.

21 January 2018

1 reference

SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis

21 January 2018

1 reference

Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum.

21 January 2018

1 reference

Spatacsin and spastizin act in the same pathway required for proper spinal motor neuron axon outgrowth in zebrafish

21 January 2018

1 reference

Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS

21 January 2018

1 reference

Ataxin-2 repeat-length variation and neurodegeneration

21 January 2018

1 reference

The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect

21 January 2018

1 reference

Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2.

21 January 2018

1 reference

Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS)

21 January 2018

1 reference

Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis

21 January 2018

1 reference

Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17

21 January 2018

1 reference

Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21

21 January 2018

1 reference

Clinicopathologic variability of the GRN A9D mutation, including amyotrophic lateral sclerosis

21 January 2018

1 reference

Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis

21 January 2018

1 reference

Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43.

21 January 2018

1 reference

HFE gene variants affect iron in the brain

21 January 2018

1 reference

Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences

21 January 2018

1 reference

HFE H63D polymorphism is increased in patients with amyotrophic lateral sclerosis of Italian origin

21 January 2018

1 reference

H63D polymorphism in the hemochromatosis gene is associated with sporadic amyotrophic lateral sclerosis in China.

21 January 2018

1 reference

Geography of HFE C282Y and H63D mutations

21 January 2018

1 reference

A mutation in the HFE gene is associated with altered brain iron profiles and increased oxidative stress in mice.

21 January 2018

1 reference

Axonal damage markers in cerebrospinal fluid are increased in ALS.

21 January 2018

1 reference

Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker

21 January 2018

1 reference

Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study

21 January 2018

1 reference

Aberrant morphology and residual transmitter release at the Munc13-deficient mouse neuromuscular synapse

21 January 2018

1 reference

Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

21 January 2018

1 reference

VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death

21 January 2018

1 reference

Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype

21 January 2018

1 reference

The neurogenomics view of neurological diseases

21 January 2018

1 reference

FUS mutations in sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

Modelling the effects of penetrance and family size on rates of sporadic and familial disease

21 January 2018

1 reference

A de novo missense mutation of the FUS gene in a "true" sporadic ALS case

21 January 2018

1 reference

Exome sequencing to identify de novo mutations in sporadic ALS trios

21 January 2018

1 reference

Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies

21 January 2018

1 reference

A genome-wide analysis of brain DNA methylation identifies new candidate genes for sporadic amyotrophic lateral sclerosis.

21 January 2018

1 reference

Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

Epigenetic regulation of motor neuron cell death through DNA methylation

21 January 2018

1 reference

Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription

21 January 2018

1 reference

Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation?

21 January 2018

1 reference

Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells

21 January 2018

1 reference

Prion-like properties of pathological TDP-43 aggregates from diseased brains

21 January 2018

1 reference

Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS

21 January 2018

1 reference

Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis

21 January 2018

1 reference

Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis

21 January 2018

1 reference

Presymptomatic studies in ALS: rationale, challenges, and approach

21 January 2018

1 reference

Implementing personalized cancer genomics in clinical trials

21 January 2018

1 reference

Antisense oligonucleotide therapy for neurodegenerative disease.

21 January 2018

1 reference

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

21 January 2018

1 reference

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis

21 January 2018

1 reference

A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data

21 January 2018

1 reference

A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.

21 January 2018

1 reference

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.

21 January 2018

1 reference

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

21 January 2018

1 reference

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

21 January 2018

1 reference

A clinical trial of creatine in ALS.

21 January 2018

1 reference

Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.

21 January 2018

1 reference

A pilot trial of dextromethorphan in amyotrophic lateral sclerosis

21 January 2018

1 reference

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial

21 January 2018

1 reference

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

21 January 2018

1 reference

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis.

21 January 2018

1 reference

Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial.

21 January 2018

1 reference

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial

21 January 2018

1 reference

Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial

21 January 2018

1 reference

A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results.

21 January 2018

1 reference

Recombinant growth hormone treatment of amyotrophic lateral sclerosis

21 January 2018

1 reference

Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

21 January 2018

1 reference

A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS.

21 January 2018

1 reference

A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters

21 January 2018

1 reference

Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis.

21 January 2018

1 reference

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial

21 January 2018

1 reference

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study

21 January 2018

1 reference

A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis

21 January 2018

1 reference

Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis

21 January 2018

1 reference

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

Controlled trial of nimodipine in amyotrophic lateral sclerosis

21 January 2018

1 reference

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

21 January 2018

1 reference

A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis

21 January 2018

1 reference

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

21 January 2018

1 reference

Phase II/III randomized trial of TCH346 in patients with ALS

21 January 2018

1 reference

Thalidomide causes sinus bradycardia in ALS.

21 January 2018

1 reference

A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis

21 January 2018

1 reference

Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease

21 January 2018

1 reference

Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system

21 January 2018

1 reference

Therapeutic trial of tilorone in ALS: Lack of benefit in a double-blind, placebo-controlled study

21 January 2018

1 reference

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

Transfer factor is ineffective in amyotrophic lateral sclerosis

21 January 2018

1 reference

Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial

21 January 2018

1 reference

Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis

21 January 2018

1 reference

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

21 January 2018

1 reference

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study

21 January 2018

1 reference

Xaliproden in amyotrophic lateral sclerosis: early clinical trials

21 January 2018

1 reference

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

21 January 2018

1 reference

ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B)

21 January 2018

1 reference

Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis

21 January 2018

1 reference

SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

A yeast functional screen predicts new candidate ALS disease genes

21 January 2018

1 reference

Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis

21 January 2018

1 reference

Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration

21 January 2018

1 reference

EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans

21 January 2018

1 reference

Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS.

21 January 2018

1 reference

Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

Lack of association of VEGF promoter polymorphisms with sporadic ALS

21 January 2018

1 reference

Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics

21 January 2018

1 reference

Progranulin genetic variability contributes to amyotrophic lateral sclerosis

21 January 2018

1 reference

The Association Between H63D Mutations in HFE and Amyotrophic Lateral Sclerosis in a Dutch Population

21 January 2018

1 reference

Association of polymorphisms in vascular endothelial growth factor gene with the age of onset of amyotrophic lateral sclerosis

21 January 2018

1 reference

?True? sporadic ALS associated with a novel SOD-1 mutation

21 January 2018

1 reference

Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis

21 January 2018

1 reference

VCP mutations in familial and sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

Association of Long ATXN2 CAG Repeat Sizes With Increased Risk of Amyotrophic Lateral Sclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MUS.24198

1 reference

1 August 2017

1 reference

PubMed ID

24488689